Last reviewed · How we verify
Oxytocin 400 i.u.
At a glance
| Generic name | Oxytocin 400 i.u. |
|---|---|
| Also known as | Vagoticin |
| Sponsor | PepTonic Medical AB |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Dose-relationship of Vaginally Administrated Oxytocin in Postmenopausal Women (PHASE2)
- Comparison of Inhaled Oxytocin (IH) With Intramuscular (IM) Oxytocin in Pregnant Women and With Intravenous (IV) Oxytocin in Healthy Non-pregnant Women (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Oxytocin 400 i.u. CI brief — competitive landscape report
- Oxytocin 400 i.u. updates RSS · CI watch RSS
- PepTonic Medical AB portfolio CI